Gyre Therapeutics Inc GYRE 深 滬
已收盤 04-02 16:00:00 美东时间
7.12
-0.110
-1.52%
華盛通- 最 高7.18
- 今 開7.04
- 成交量 6.35万股
- 最 低 6.91
- 昨 收 7.23
- 總市值 6.50亿
- 52周最高 11.78
- 市盈率 靜 316.44
- 換手率 0.07%
- 52周最低 6.57
- 委 比 83.37%
- 總股本 9131.40万
- 歷史最高 29271.2116
- 量 比 0.61
- 振 幅 3.73%
- 歷史最低 -19.80
- 每 手 1
- 風險率 0.85%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Gyre Therapeutics submits Hydronidone NDA to China NMPA for CHB-induced liver fibrosis
Gyre Therapeutics submits Hydronidone NDA to China NMPA for CHB-induced liver fibrosis Gyre said its majority indirectly owned subsidiary Gyre Pharmaceuticals submitted a New Drug Application to China’s National Medical Products Administration’s Center for Drug Evaluation for F351 (Hydronidone). The
03-23 19:51
BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting Goods
BUZZ-U.S. STOCKS ON THE MOVE-Bumble, Dick's Sporting Goods Workspace search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 March 12 (Reuters) - U.S. stock index futures fell on Thursday as oil p
03-12 19:52
Earnings Scheduled For March 12, 2026
Companies Reporting Before The Bell • Seres Therapeutics (NASDAQ:MCRB) is likel...
03-12 19:11
Gyre Therapeutics sees F351 liver fibrosis revenue potential of USD 400-600 million within five years
Gyre Therapeutics sees F351 liver fibrosis revenue potential of USD 400-600 million within five years Gyre said it sees potential liver fibrosis revenue of about USD 400-600 million within five years for Hydronidone (F351), based on patient population data. The company also said it expects ETUARY re
03-12 18:32
Gyre Therapeutics Sees FY2026 Sales $100.500M-$111.000M vs $146.133M Est
Gyre Therapeutics (NASDAQ:GYRE) sees FY2026 sales of $100.500 million-$111.000 million vs $146.133 million analyst estimate.
03-12 18:17
Gyre Therapeutics Q4 Adj. EPS $0.05 Misses $0.06 Estimate, Sales $37.195M Beat $36.303M Estimate
Gyre Therapeutics (NASDAQ:GYRE) reported quarterly earnings of $0.05 per share which missed the analyst consensus estimate of $0.06 by 26.98 percent. This is a 253.85 percent increase over earnings of $0.01 per share
03-12 18:16
Gyre Therapeutics Q4 revenue beats estimates on new product launch
Gyre Therapeutics Q4 revenue beats estimates on new product launch Overview US biopharma firm's Q4 revenue rose 33% yr/yr, beating analyst expectations Company posted a Q4 net loss as operating expenses increased sharply Gyre expects 2026 revenue to decline as it prioritizes regulatory activities an
03-12 18:09
Gyre Therapeutics Q4 revenue rose 33% to USD 37.2 million as Q4 selling and marketing expense climbed 41% to USD 23.8 million
Gyre Therapeutics Q4 revenue rose 33% to USD 37.2 million as Q4 selling and marketing expense climbed 41% to USD 23.8 million Gyre reported Q4 revenue of USD 37.2 million, up 33% year over year, driven by higher ETUARY sales and contributions from Etorel and Contiva launches. Q4 net loss was USD 1.4
03-12 18:07
Gyre Therapeutics Strikes All-Stock Agreement To Acquire Cullgen For ~$300M
Gyre Therapeutics, Inc. (Gyre or the Company) (NASDAQ:GYRE), an innovative, commercial-stage biopharmaceutical company dedicated to advancing fibrosis-first therapies across organ systems affected by chronic diseases,
03-02 21:01
Gyre Therapeutics Showcases Pipeline Progress and Market Leadership in Anti-Fibrotic Therapies
Gyre Therapeutics Showcases Pipeline Progress and Market Leadership in Anti-Fibrotic Therapies Gyre Therapeutics Inc. highlighted its leadership in the treatment of idiopathic pulmonary fibrosis (IPF) in China, with its product ETUARY® (pirfenidone) maintaining the largest market share for ten conse
01-28 06:02
